Deciphering the potential protective mechanisms of amygdalin in ischemic stroke through network pharmacology and in vitro experiments
Letters in Drug Design & Discovery · 2026-09 · 23 (9) · 100584
DOI: 10.1016/j.lddd.2026.100584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-09. Verfasst von Xiaowen Wu und 5 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Education Department of Hainan Province.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Ischemic stroke (IS) is an acute cerebrovascular disease that seriously endangers human health. Amygdalin, a natural cyanogenic glycoside, has neuroprotective effects, but its protective role, specific targets, and underlying mechanisms in IS remain unclear, warranting systematic investigation.
Methods
The GeneCards and SwissTarget databases were utilized for target collection. Shared targets were analyzed via protein-protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Amygdalin was docked with the top-ranked targets in the PPI network through molecular docking. Then, in vitro functional assays were carried out for verification. Cell viability was examined by the Cell Counting Kit-8. Western blot was used to evaluate protein levels. Reactive oxygen species (ROS) levels, cell apoptosis and inflammatory response were analyzed using commercial kits, flow cytometry and enzyme-linked immunosorbent assay. Cellular Thermal Shift Assay (CETSA) and fluorogenic DQ™-gelatin assay were additionally applied to verify direct binding and enzymatic inhibition between amygdalin and matrix metalloproteinase-9 (MMP-9).
Results
Sixty intersection genes between amygdalin and IS were screened out, and five core genes were identified according to the degree value. Functional enrichment analyses indicated that amygdalin might influence biological processes in IS, such as protein phosphorylation. Molecular docking predicted favorable binding for all five targets, with binding energies ranging from −10.5 to −6.6 kcal/mol. Based on its well-documented role in ischemia/reperfusion-induced endothelial injury, MMP-9 was prioritized for subsequent functional validation. Oxygen Glucose Deprivation/Reperfusion treatment significantly reduced human brain microvascular endothelial cells (HBMVEC) viability ( P < 0.001). CETSA revealed a thermal-shift effect for MMP-9 upon amygdalin treatment, suggesting potential target engagement between amygdalin and MMP-9. MMP-9 overexpression completely abolished the anti-oxidative, anti-apoptotic and anti-inflammatory effects of amygdalin ( P < 0.05, P < 0.01, or P < 0.001).
Conclusion
This study identified MMP-9 as a key functional target of amygdalin in IS in vitro , providing a preclinical rationale for further investigation of its potential therapeutic applications.
Förderung
- Education Department of Hainan Province
Zitieren
APA
Wu, X., Pan, J., Huang, S., Xu, Z., Chen, M., & Li, P. (2026). Deciphering the potential protective mechanisms of amygdalin in ischemic stroke through network pharmacology and in vitro experiments. Letters in Drug Design & Discovery, 23(9), 100584. https://doi.org/10.1016/j.lddd.2026.100584
Vancouver
Wu X, Pan J, Huang S, Xu Z, Chen M, Li P. Deciphering the potential protective mechanisms of amygdalin in ischemic stroke through network pharmacology and in vitro experiments. Letters in Drug Design & Discovery. 2026;23(9):100584. doi:10.1016/j.lddd.2026.100584
BibTeX
@article{Wu2026,
author = {Wu, Xiaowen and Pan, Jiaxing and Huang, Shaozhu and Xu, Zhongzhong and Chen, Min and Li, Pengxiang},
title = {Deciphering the potential protective mechanisms of amygdalin in ischemic stroke through network pharmacology and in vitro experiments},
journal = {Letters in Drug Design & Discovery},
year = {2026},
volume = {23},
number = {9},
pages = {100584},
doi = {10.1016/j.lddd.2026.100584}
}
EUVIMED